Table 4. Quality of Anticoagulant Use by Race/Ethnicity.
| Characteristic | Patients Overall | White Patients | Black Patients | Hispanic Patients | P Value |
|---|---|---|---|---|---|
| Warfarin | |||||
| No. | 1704 | 1462 | 121 | 121 | |
| Time in therapeutic range during follow-up, median (IQR), %a | 66.0 (50.0-79.3) | 67.1 (51.8-80.6) | 57.1 (39.9-72.5) | 51.7 (39.1-66.7) | <.001 |
| Time spent with international normalized ratio, %, median (IQR) | |||||
| <2 | 17.0 (5.7-31.6) | 16.0 (5.0-29.4) | 20.0 (8.7-41.2) | 27.4 (15.5-41.0) | <.001 |
| >3 | 10.8 (1.4-21.2) | 10.4 (0.8-20.4) | 11.5 (2.5-22.4) | 13.5 (2.2-23.6) | .23 |
| Dose of direct-acting oral anticoagulant, No. (%) | |||||
| No. | 8791 | 7988 | 394 | 409 | |
| Underdose | 824 (9.4) | 726 (9.1) | 44 (11.2) | 54 (13.2) | .01 |
| Appropriate | 7653 (87.1) | 6985 (87.4) | 333 (84.5) | 335 (81.9) | |
| Excessive | 314 (3.6) | 277 (3.5) | 17 (4.3) | 20 (4.9) |
Abbrevation: IQR, interquartile range.
a
Missing 26.1% of data in the time in therapeutic range in follow-up overall, including 26.1% of white patients, 28.1% of black patients, and 24.8% of Hispanic patients.